Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Zhejiang University School of Medicine | United Kingdom

Dr. Sakarie Mustafe Hidig is a General Surgeon, Clinical Researcher, and Editor-in-Chief affiliated with Zhejiang University School of Medicine and the Research Center at Hargeisa Group Hospital. He serves as the UK Country Coordinator for the International Institute of Knowledge Management (TIIKM) and is an active member of the China Medical Association, Somali Medical Association, and the Scholars Academic and Scientific Society. Dr. Hidig has earned multiple international honors, including the SHEN Best Researcher Awards, GCDMSE-2024, and ISSN Research Awards. With over 70 published papers, 280+ SCI editorial handling experiences, and 14 research projects, his work spans general, gastrointestinal, trauma, emergency, hepatobiliary, and pancreatic surgery. He also contributes as an editor for major journals such as PLOS One Medicine, Annals of Medicine and Surgery, Obesity Surgery, and JMIR Public Health and Surveillance. His research interests include surgical oncology, hepatology, pancreatic cancer, and public health.

Citation Metrics (Scopus)

40

30

20

10

0

Citations
12

Documents
7

h-index
2

Citations
Documents
h-index



View Scopus Profile

Featured Publication

Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Wake Forest School of Medicine | United States

Dr. Waldemar Debinski, M.D., Ph.D., is a distinguished neuroscientist and cancer researcher recognized for his pioneering work in brain tumor biology and targeted molecular therapies. His research focuses on understanding the molecular mechanisms that drive the development and progression of malignant brain tumors, with a particular emphasis on gliomas. Dr. Debinski has significantly contributed to the development of novel targeted therapeutics, including receptor-directed cytotoxins and biologics designed to selectively eliminate tumor cells while sparing healthy tissues. His investigations bridge molecular oncology, translational science, and clinical application, aiming to improve therapeutic outcomes for patients with brain cancers. Throughout his career, he has integrated insights from physiology, molecular biology, and pharmacology to develop translational approaches that move from laboratory discovery to clinical implementation. His extensive research has advanced the understanding of tumor-specific receptors and intracellular signaling pathways, contributing to innovative strategies in cancer immunotherapy and precision medicine. Dr. Debinski’s work exemplifies the integration of basic and clinical research toward the development of next-generation treatments for central nervous system malignancies, positioning him as a leading figure in neuro-oncology and translational cancer research.

Profile: Scopus

Featured Publications:

Wocial, B., Januszewicz, W., Siedlecki, J., Feltynowski, T., & Debinski, W. (1982). Alterations in plasma dopamine-β-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma. Endocrinologie, 79, 131–139.

Debinski, W., & Wocial, B. (1982). Various aspects of sodium metabolism in hypertension [in Polish]. Polski Tygodnik Lekarski, 37, 1339–1342.

Ignatowska-Świtalska, H., Debinski, W., & Chojnowski, K. (1983). The role of certain hormonal factors in arterial hypertension [in Polish]. Materia Medica Polona, 15, 74–86.

Wasawska, T., Feltynowski, T., Majewska, Z., Januszewicz, W., Sobolewska-Karwowska, A., Wocial, B., & Debinski, W. (1984). Pheochromocytoma: Description of two cases with an unusual clinical picture [in Polish]. Polski Tygodnik Lekarski, 39, 261–263.

Czarkowski, M., & Debinski, W. (1984). Sodium and primary arterial hypertension [in Polish] (Review). Kardiologia Polska, 27, 967–976.

Wocial, B., Debinski, W., Jablonska-Skwicinska, E., Feltynowski, T., Chodakowska, J., Kozakowska, E., & Januszewicz, W. (1984). Sodium content of erythrocytes in patients with arterial hypertension [in Polish]. Polski Archiwum Medycyny Wewnetrznej, 72, 167–174.

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., & Cantin, M. (1985). Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochemical and Biophysical Research Communications, 131, 806–814.

Debinski, W., Kuchel, O., Garcia, R., Buu, N. T., Racz, K., Cantin, M., & Genest, J. (1986). Atrial natriuretic factor inhibits sympathetic activity in one-kidney, one-clip hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine, 181, 173–177.

Debinski, W., Kuchel, O., Buu, N. T., Garcia, R., Cantin, M., & Genest, J. (1986). Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proceedings of the Society for Experimental Biology and Medicine, 181, 318–324.

Debinski, W., Gutkowska, J., Kuchel, O., Racz, K., Buu, N. T., Cantin, M., & Genest, J. (1986). ANF-like peptide(s) in the peripheral autonomic nervous system. Biochemical and Biophysical Research Communications, 134, 279–284.

Yi Zhang | Tumor Immunology | Best Researcher Award

Published on by Cell Biologist

Prof. Yi Zhang | Tumor Immunology | Best Researcher Award

The First Affiliated Hospital of Zhengzhou University | China

Prof. Yi Zhang is a globally recognized leader in genetically engineered cell therapy and translational immuno-oncology research. Over the past 36 years, he has made pioneering contributions to overcoming major barriers in cell therapy and advancing its clinical applications worldwide. His extensive research has produced 290 SCI-indexed publications, including 11 ESI top 1% highly cited papers, accumulating more than 14,000 citations and an h-index of 66. Prof. Zhang’s groundbreaking innovations include identifying the novel CAR-T therapeutic target CD276 for solid tumors, developing gene-editing technologies to reduce PD-1–mediated immunosuppression, and creating novel cytokines and culture protocols that enhance immune cell stemness and anti-tumor function. He has also led the development of CAR-T cells that normalize tumor vasculature and improve infiltration, significantly enhancing therapeutic efficacy. With 46 invention patents (17 authorized) and over 80 million yuan in technology transfers, his work bridges basic science and clinical application through an integrated “industry-university-research” platform. As principal investigator, he has directed more than 52 clinical trials—29 targeting solid tumors, the highest number globally—resulting in improved outcomes and even clinical cures for advanced cancer patients. His leadership in establishing national standards and safety protocols has also shaped the regulation and global best practices in cell therapy.

Profile: Orcid

Featured Publications:

Gao, Y., Liu, S., Huang, Y., Wang, H., Zhao, Y., Cui, X., Peng, Y., Li, F., & Zhang, Y. (2024, December 3). CAR T cells engineered to secrete IFNκ induce tumor ferroptosis via an IFNAR/STAT1/ACSL4 axis. Cancer Immunology Research.

Huang, Y., Cao, R., Wang, S., Chen, X., Ping, Y., & Zhang, Y. (2025, December 31). In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy. Human Vaccines & Immunotherapeutics.

Li, J., Wang, D., Zhang, Z., Sun, K., Lei, Q., Zhao, X., Huang, J., Wang, L., & Zhang, Y. (2025, June 1). Serum carcinoembryonic antigen levels as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with colorectal cancer. The Journal of Immunology.

Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2025, March 5). Correction: Immunosenescence: A key player in cancer development. Journal of Hematology & Oncology.

Ping, Y., Fan, Q., & Zhang, Y. (2025, February). Modulating lipid metabolism improves tumor immunotherapy. Journal for ImmunoTherapy of Cancer.

Hu, W., Li, F., Liang, Y., Liu, S., Wang, S., Shen, C., Zhao, Y., Wang, H., & Zhang, Y. (2025, January). Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors. Journal for ImmunoTherapy of Cancer.

Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Published on by Cell Biologist

Dr. Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Edinburgh of University | United Kingdom

Dr. Amirhosein Kefayat is a clinical research fellow at the Institute of Genetics and Cancer, University of Edinburgh, with over fourteen years of dedicated experience in translational and clinical cancer research. Since his early days in medical school, he has pursued a strong passion for advancing oncology through both laboratory and clinical investigations, contributing to more than 60 peer-reviewed publications that have collectively garnered over 2,300 citations, with a Google Scholar H-index of 28. His research spans biomaterials, nanomedicine, wound healing, immunoinformatics, and cancer vaccine design, with several of his papers ranking among the top 1% most-cited in their respective years of publication. Notably, his work on innovative wound dressings, cancer-testis antigen vaccines, and gold nanoclusters for radiosensitization has made significant impacts within the fields of biomaterials and cancer therapeutics. Alongside his research, he is currently advancing his academic qualifications through a Postgraduate Certificate of Academic Practice at the University of Edinburgh and Associate Principal Investigator Training with NIHR. Recognized among the top 0.5% of cancer researchers worldwide, his career reflects a consistent commitment to bridging basic science and clinical application to improve patient care.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Eskandarinia, A., Kefayat, A., Agheb, M., Rafienia, M., Amini Baghbadorani, M., & Navid, S. (2020). A novel bilayer wound dressing composed of a dense polyurethane/propolis membrane and a biodegradable polycaprolactone/gelatin nanofibrous scaffold. Scientific Reports, 10(1), 3063.

Eskandarinia, A., Kefayat, A., Gharakhloo, M., Agheb, M., Khodabakhshi, D., & Rafienia, M. (2020). A propolis enriched polyurethane-hyaluronic acid nanofibrous wound dressing with remarkable antibacterial and wound healing activities. International Journal of Biological Macromolecules, 149, 467–476.

Safavi, A., Kefayat, A., Mahdevar, E., Abiri, A., & Ghahremani, F. (2020). Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine, 38(48), 7612–7628.

Khodabakhshi, D., Eskandarinia, A., Kefayat, A., Rafienia, M., Navid, S., & Karbasi, S. (2019). In vitro and in vivo performance of a propolis-coated polyurethane wound dressing with high porosity and antibacterial efficacy. Colloids and Surfaces B: Biointerfaces, 178, 177–184.

Eskandarinia, A., Kefayat, A., Rafienia, M., Agheb, M., Navid, S., & Ebrahimpour, K. (2019). Cornstarch-based wound dressing incorporated with hyaluronic acid and propolis: In vitro and in vivo studies. Carbohydrate Polymers, 216, 25–35.

HEMAMALINI MADHUKAR | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. HEMAMALINI MADHUKAR | Cancer Cell Biology | Best Researcher Award

Dr. HEMAMALINI MADHUKAR, Mother Teresa Women’s University, India

Dr. Madhukar Hemamalini is an accomplished Assistant Professor in the Department of Chemistry at Mother Teresa Women’s University, Kodaikanal. With over five and a half years of dedicated research experience and eight years of teaching, she has made significant contributions to the field of structural and bioorganic chemistry. Her expertise lies in X-ray crystallography, protein-ligand interactions, and the synthesis of supramolecular and pharmaceutical compounds. She earned her Ph.D. in Chemistry from Bharathidasan University and completed a postdoctoral fellowship under Prof. H.-K. Fun at Universiti Sains Malaysia. With 234 international publications and a citation index reflecting her research impact, Dr. Hemamalini’s academic presence is both global and influential. Her guidance to 10 M.Phil. and 21 M.Sc. students reflects her commitment to mentoring the next generation of scientists. She actively contributes to academic committees and has led a UGC Minor Research Project on hydrogen bonding and phase transition.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Extensive Publication Record

    • Over 234 international research publications, primarily in reputed journals such as Journal of Molecular Structure, Molecular Diversity, Russian Journal of Inorganic Chemistry, and IUCrData.

    • Research themes include X-ray crystallography, drug-likeness prediction, molecular docking, and biochemical analysis.

  2. Strong Research Background

    • Postdoctoral research in crystallography at Universiti Sains Malaysia (USM) under a globally respected crystallographer, Prof. H.-K. Fun.

    • More than five and a half years of focused research experience in supramolecular and macromolecular chemistry.

  3. Citation Impact

    • Accumulated 228 citations, with a h-index of 12 and i10-index of 8, reflecting a solid impact in her field.

  4. Mentorship & Teaching

    • 8 years of teaching experience as an Assistant Professor.

    • Mentored 10 M.Phil. and 21 M.Sc. students — demonstrating her commitment to research training and knowledge dissemination.

  5. Research Funding

    • Successfully secured UGC Minor Research Project funding of ₹5,00,000 for studies on hydrogen bonding and phase transition.

  6. Academic Service

    • Contributed to institutional growth as inspection committee member for women’s colleges, affirming leadership in academic governance.

⚠️ Areas for Improvement:

  1. Enhance International Collaboration

    • Collaborations beyond Malaysia, particularly with Europe or North America, could increase citation visibility and interdisciplinary reach.

  2. Diversify Funding Sources

    • Apply for major national/international grants (e.g., DST, DBT, SERB, or industry-academic partnerships) for scaling research infrastructure and student involvement.

  3. Intellectual Property & Innovation

    • Translating research into patents, prototypes, or industry consultancies would enhance her research’s practical value and real-world impact.

  4. Public Engagement and Outreach

    • Participation in conferences as keynote speaker, science communication, or popular science articles would further establish her academic persona.

🎓 Education:

Dr. Madhukar Hemamalini completed her Ph.D. in Chemistry in October 2006 from Bharathidasan University, India, specializing in structural and supramolecular chemistry. Her doctoral research focused on the synthesis and crystallographic analysis of organic compounds, laying a strong foundation for her future work in macromolecular systems. Prior to her doctorate, she obtained her M.Sc. in Chemistry in August 2000 and B.Sc. in Chemistry in August 1998, both from Bharathidasan University. Her academic training has equipped her with a deep understanding of chemical interactions at the molecular level, especially those relevant to drug design, protein-ligand binding, and pharmaceutical solids. Her academic trajectory showcases her longstanding passion for exploring the molecular world through advanced techniques like X-ray crystallography and computational chemistry. Additionally, her exposure to interdisciplinary research at Universiti Sains Malaysia has expanded her global outlook and enriched her research methodologies.

🧪 Experience:

Dr. Hemamalini has a cumulative 13+ years of experience in academia and research. She is currently serving as Assistant Professor at the Department of Chemistry, Mother Teresa Women’s University, Kodaikanal since March 2015. Her teaching portfolio includes mentoring postgraduate and M.Phil. students, with 21 M.Sc. and 10 M.Phil. students successfully guided under her supervision. From December 2009 to February 2012, she pursued Post-Doctoral research in X-ray crystallography at Universiti Sains Malaysia under the mentorship of Prof. H.-K. Fun, focusing on supramolecular motifs and metal coordination complexes. Her total research experience spans over five and a half years, during which she explored protein-ligand interactions, crystal engineering, and bioorganic compound synthesis. She also participated in institutional academic committees and inspection boards, contributing to higher education quality assurance. Her dual expertise in both teaching and high-impact research makes her a well-rounded academic professional.

🏆 Awards and Honors:

Dr. Madhukar Hemamalini has been the recipient of the prestigious Senior Research Fellowship (SRF) from the Council of Scientific and Industrial Research (CSIR), New Delhi (2004–2006), which stands as a testimony to her research potential and academic rigor. In addition to this major national honor, she has been involved in several university-level academic panels, including Inspection Committees for women’s colleges in Dindigul, highlighting her contributions to academic governance and quality control. Her funded project under the UGC Minor Research Project Scheme—with a sanctioned amount of ₹5,00,000—focused on the hydrogen bonding interactions and phase transition studies in organic compounds, an area of current interest in molecular chemistry. Her work has been cited over 228 times, and she holds a h-index of 12 and an i10-index of 8, reflecting a consistent and meaningful research output across international journals.

🔬 Research Focus:

Dr. Hemamalini’s research revolves around X-ray crystallography, macromolecular chemistry, and supramolecular design. Her scientific interest lies in unraveling structure–function relationships in molecules, particularly in protein-ligand complexes, bioorganic frameworks, and pharmaceutical solids. She has applied her expertise in both experimental (e.g., crystal growth and structural analysis) and computational techniques (e.g., molecular docking, dynamics simulations) to synthesize novel compounds with potential drug-like behavior. Her interdisciplinary approach bridges chemistry with biology, enabling her to work on problems like TNF-α inhibition in rheumatoid arthritis, anti-cancer screening, and antidiabetic compound design. She has actively published in reputed journals, showcasing both synthetic and theoretical studies. Her postdoctoral training at Universiti Sains Malaysia helped her master crystallographic techniques, further enriching her analytical capabilities. Her work continues to contribute valuable insights into biomolecular recognition, drug-receptor modeling, and material science.

📚 Publications Top Notes: 

  1. 📄 Synthesis of 3-Methoxy…phenol Schiff base: spectral, in-silico & in-vitro studies – Heliyon, 2022

  2. 🧬 In silico and in vitro identification of TNF-α inhibitors from Euphorbia hirta for rheumatoid arthritis – Molecular Diversity, 2025

  3. 💊 Anti-diabetic activity of pyrimidinium-hydrogen oxalate conjugates: synthesis, docking & simulation – Journal of Molecular Structure, 2025

  4. 🧪 [2-(1H-indol-3-yl)ethyl]-(4-nitrobenzylidene)amine: anti-breast cancer & antibacterial insights – Journal of Molecular Structure, 2025

  5. 🔬 PPI networking, expression analysis & TNF-α inhibitor screening for RA – Molecular Diversity, 2025

  6. 🧫 6-Bromo-9,9-diethyl-N,N-diphenylfluoren-2-amine – Data Paper

  7. 🧊 Insights into oxidovanadium porphyrin: synthesis & Hirshfeld surface analysis – Journal of Molecular Structure, 2024

  8. 🧬 1,4-Dimethylpiperazine-2,3-dione – crystal structure study – Iucrdata, 2024

  9. ⚗️ (1H-Benzodiazol-2-ylmethyl)diethylamine – molecular characterization – Iucrdata, 2024

  10. 🔍 Structural & oxidative studies of (3,4,5-trimethoxyphenyl)Porphyrin Ni(II) Complex – Russian Journal of Inorganic Chemistry, 2024

🧾 Conclusion:

Dr. Madhukar Hemamalini possesses a well-rounded academic profile with consistent research output, teaching excellence, mentorship, and academic service. Her work in structural and medicinal chemistry, particularly involving crystallography and biomolecular interactions, has practical implications in drug discovery and material science. She demonstrates all the key markers of a successful and impactful researcher.

Yanlan Wang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Yanlan Wang | Cancer Cell Biology | Best Researcher Award

Dr. Yanlan Wang, Stanford, United States

Dr. Yanlan Wang is a distinguished postdoctoral research fellow at Stanford University’s Department of Pathology. She works in the esteemed Dr. Gerald Crabtree’s lab, where her research revolves around leveraging molecular glues to reprogram cancer drivers and trigger apoptosis. With a strong background in immuno-oncology, antibody engineering, and small molecule therapeutics, Dr. Wang has made significant contributions to targeted cancer therapies. Her interdisciplinary collaborations, notably with Dr. Nathanael Gray’s group, have explored the role of transcription factor complex-inducing compounds (TCIPs) in MLL-rearranged leukemia. Dr. Wang brings a rich international research experience from China and the U.S., with a career spanning translational medicine, biotechnology innovation, and academic excellence. She is known for her rigorous approach to scientific inquiry, collaborative spirit, and prolific publication record. Her passion for understanding and overcoming the mechanisms of cancer resistance positions her as a future leader in oncology drug development and precision medicine.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Outstanding Research Focus
    Dr. Wang’s work on molecular glues and transcription factor modulators represents cutting-edge approaches in cancer therapy, especially in targeting previously undruggable pathways.

  2. High Impact Publications
    With multiple first-author and co-corresponding author papers (e.g., J Immunol Methods 2025, Leukemia & Lymphoma 2020, Clin Pharmacol Ther 2021), Dr. Wang has demonstrated a strong track record in both fundamental and translational cancer research.

  3. Innovation & Translational Impact
    Her efforts in bispecific antibody engineering, IL-15 therapeutics, and AKR1C3-targeted prodrugs show clear applications in oncology drug development, bridging the lab and clinic.

  4. Prestigious Collaborations
    Collaborating with renowned researchers such as Dr. Gerald Crabtree and Dr. Nathanael Gray at Stanford indicates high confidence and integration in world-class research circles.

  5. Recognition & Awards
    She has received the Coxe Fellowship at Stanford and multiple merit-based scholarships, highlighting academic excellence and innovation.

  6. Leadership and Multidisciplinary Skills
    Dr. Wang has led several projects, authored high-level papers, and mentored junior researchers, showcasing both technical and leadership capability.

🔄 Areas for Improvement:

  1. Greater International Presentation Exposure
    Although she has strong publication credentials, more visibility through international oral presentations, keynote addresses, or panel roles would amplify her leadership profile.

  2. Independent Grant Record
    While she is currently in a postdoctoral role, seeking independent funding (e.g., K99/R00, early-career PI grants) would position her more competitively for independent investigator status.

  3. Patent or Commercial Translation
    Given the translational nature of her work, pursuit of intellectual property filings or biotech partnerships would further highlight impact.

🎓 Education:

Dr. Yanlan Wang began her academic journey at Xiangya School of Medicine, Central South University, where she earned her MBBS (M.D. equivalent) in June 2012. She continued at The Second Xiangya Hospital for her clinical residency, completing her M.S. in June 2015. Her pursuit of scientific excellence led her to earn a doctorate (M.D. equivalent to PhD) from Sun Yat-sen University in June 2018, with a research focus on microbial immunology and tumor biology. This diverse educational background gave her a solid foundation in both clinical medicine and biomedical research, allowing her to bridge translational gaps in cancer research. Her early training emphasized immunotherapy, molecular biology, and oncology, all of which paved the way for her postdoctoral work in cutting-edge labs. Her education reflects a consistent upward trajectory, marked by prestigious institutions, interdisciplinary training, and a seamless integration of clinical and scientific disciplines.

🔬 Experience:

Dr. Yanlan Wang is currently a postdoctoral research fellow in Dr. Gerald Crabtree’s lab at Stanford University, where she focuses on manipulating cancer cell pathways using molecular glues. Her prior research in China included pivotal roles in biotechnology innovation, including bispecific antibody engineering, prodrug design, and immune-oncology drug development. She has also collaborated extensively with Dr. Nathanael Gray’s lab at Stanford, exploring the therapeutic potential of TCIPs in leukemia. Dr. Wang’s hands-on experience includes multiplex screening platforms, flow cytometry, in vivo tumor models, and translational immunotherapy development. Over the years, she has taken leadership roles in preclinical projects, manuscript authorship, and international scientific presentations. Her diverse roles—from clinical residency to laboratory innovation—reflect her capability to translate complex scientific findings into therapeutic strategies. Dr. Wang has also mentored junior researchers and worked across multiple disciplines, underscoring her adaptability, leadership potential, and deep commitment to cancer research.

🏅 Awards and Honors:

Dr. Yanlan Wang’s excellence has been recognized through several prestigious awards. At Stanford, she received the Coxe Fellowship in 2021, honoring outstanding postdoctoral researchers. During her doctoral training, she earned the Special Award of Merit for the BJ-001 Project at BJ Bioscience Inc. in 2019 for her impactful translational research. Her academic merit was consistently acknowledged through the Bidi Scholarship (2016–2017) and Daxiang Scholarship (2015–2016) at Sun Yat-sen University. These honors underscore her commitment to scientific excellence, innovation, and translational impact in oncology and immunotherapy. Her ability to receive awards across both academic and industrial settings highlights her versatility and the real-world relevance of her work. These distinctions serve as a testament to her leadership in cancer drug development, collaborative effectiveness, and contribution to next-generation therapeutic discoveries.

🔍 Research Focus:

Dr. Yanlan Wang’s research lies at the intersection of cancer biology, molecular pharmacology, and immunotherapy. At Stanford, she investigates how molecular glues can be used to hijack cancer drivers and activate apoptosis, offering a novel route for targeted cancer therapies. Her work involves multiplex molecular glue screening, understanding protein degradation pathways, and designing synthetic lethality strategies. In collaboration with Dr. Nathanael Gray, she is also studying Transcription factor Complex-Inducing Compounds (TCIPs) for the treatment of MLL-rearranged leukemia, a particularly aggressive form of blood cancer. Prior to this, her research focused on bispecific antibodies, prodrugs, and IL-15 based immunotherapeutics, with a vision to decouple efficacy from toxicity. Through a blend of basic science and translational applications, she aims to rewire oncogenic signaling pathways and enhance anti-tumor immunity. Her research combines drug discovery, systems biology, and precision oncology, pushing the boundaries of targeted cancer treatment.

📚 Publications Top Notes:

  1. 🔬 Quantitative flow cytometry using quantitative streptavidin-protein G-biotin beads (qBeads) – J Immunol Methods, 2025

  2. 🧬 A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-directed Cell Death – Cell (revising)

  3. 💉 Enhance IL15 anti-tumor efficacy by inhibiting its negative feedback mechanism – (in preparation)

  4. ⚛️ Decouple the toxicity and efficacy of BJ-001, an integrin targeting IL-15 – AACR Abstract, 2019

  5. 🔄 Decoupling the toxicity and efficacy of immunotherapeutics – SITC Abstract, 2019

  6. 🧪 An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL – Leukemia & Lymphoma, 2020

  7. 🧫 A novel AKR1C3 specific prodrug TH3424 with potent anti-tumor activity in liver cancer – Clin Pharmacol Ther, 2021

  8. 🧲 A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity – J Vis Exp, 2018

  9. 🧠 Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies – Cancer Biol Ther, 2020

  10. 🧿 Bp-Bs, a novel T-cell engaging bispecific antibody with biparatopic Her2 binding – Mol Ther Oncolytics, 2019

  11. 🧰 A novel multi-functional anti-CEA-IL15 molecule displays potent anti-tumor activities – Drug Des Devel Ther, 2018

  12. 🧠 A single domain based anti-Her2 antibody has potent anti-tumor activities – Transl Oncol, 2018

🧾 Conclusion:

Dr. Yanlan Wang is highly deserving of the Best Researcher Award. Her contributions to cancer therapeutics through novel molecular approaches, her collaborations with globally renowned labs, and her publication record reflect a researcher of exceptional caliber and promise. With a deep understanding of tumor biology, a commitment to innovation, and a growing leadership presence in oncology research, she is not only suitable for the award but stands as a strong role model for future biomedical researchers.